VVOS Earnings Prediction
The chart below shows how VVOS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VVOS sees a +1.38% change in stock price 10 days leading up to the earnings, and a +28.06% change 10 days following the report. On the earnings day itself, the stock moves by +6.65%. This data can give you a slight idea of what to expect for the next quarter's release.
VVOS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.86M
16.93%
-4.79%
Gross Margin
56.68%
7.04%
-8.31%
Operating Margin
-68.52%
-35.18%
43.47%
Net Margin
-67.77%
6.88%
42.34%
EPS
-0.40
-77.14%
-33.33%
No Data Available
VVOS Earnings Analysis
Vivos Therapeutics, Inc. Common Stock Corporation (VVOS.O) Earnings Conference Call
Positive
Quarterly Revenue Increase: Total revenue for Q3 2024 was $3.9 million, compared to $3.3 million for Q3 2023, representing a 17% increase quarter-over-quarter.
Product Revenue Increase: Product revenue increased by approximately $0.5 million due to higher sales of Vivus appliances and guides, coupled with lower discounts on Vivus appliances.
Service Revenue Increase: Service revenue increased by $100,000, reflecting early recognition of deferred enrollment revenue and an increase in sponsorship, seminar, and other service revenue.
Gross Profit Increase: Gross profit for Q3 2024 was $2.3 million, an increase of $600,000, or 34%, compared to Q3 2023.
Gross Margin Improvement: Gross margin for Q3 2024 was 60% compared to 53% in Q3 2023.
Negative
Quarterly Revenue Increase: Total revenue for the third quarter of 2024 was $3.9 million, compared to $3.3 million for the third quarter of 2023, indicating a 17% increase quarter-over-quarter, but still below expectations.
Revenue Decrease Analysis: The revenue decrease was impacted by our shift in sales and marketing strategy to focus on sleep provider affiliations, offset by higher incidence of breakage in contracts.
Increased Net Loss: We reported a net loss for the third quarter of 2024 increased by 25% to $2.6 million compared to the same quarter in 2023 due to primarily a third quarter change in the fair value of a warrant liability.
Operating Loss Reduction: Operating loss decreased by $4.8 million or 36% compared to the same period in 2023, indicating ongoing challenges in achieving profitability despite cost-cutting measures.
Gross Profit Increase Amid Challenges: Despite a reported increase in gross profit to $2.3 million for the third quarter of 2024, the overall financial performance remains under pressure with significant operational challenges.
VVOS FAQs
How does VVOS typically perform around its earnings report dates?
Is Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VVOS Earning Call Sentiment
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VVOS.O
7.87%Positive
The earnings call summary highlights significant improvements: increased revenue, gross profit, and margins, alongside decreased expenses and operating loss. The strategic alliance and FDA clearance offer growth potential. Although net loss increased due to warrant liability, cash position and stockholders' equity improved. The Q&A reveals optimism in marketing expansion and revenue growth, despite some uncertainties in revenue impact from new CPT codes. Overall, the positive financial performance and strategic developments suggest a positive stock price movement.